Search alternatives:
ng decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
mg decrease » _ decrease (Expand Search), we decrease (Expand Search), mean decrease (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
Showing 981 - 1,000 results of 33,023 for search '(( 50 ((ng decrease) OR (a decrease)) ) OR ( 5 ((mg decrease) OR (nn decrease)) ))', query time: 1.01s Refine Results
  1. 981
    Decreasing pixel differences caused by worm movement correspond to decreasing locomotive health.

    Decreasing pixel differences caused by worm movement correspond to decreasing locomotive health. by Areta Jushaj (8525655)

    Published 2020
    Save to List
    Saved in:
  2. 982
    Transient neonatal olfactory deprivation causes a persistent decrease in the addition of CR+ PGCs. A

    Transient neonatal olfactory deprivation causes a persistent decrease in the addition of CR+ PGCs. A by Yasuko Kato (122938)

    Published 2012
    “…. & reopening group was used as a control (control). The number of PGCs was quantified at P61. …”
    Save to List
    Saved in:
  3. 983
    Decreased nephrin expression.

    Decreased nephrin expression. by Sandra Müller-Krebs (485766)

    Published 2013
    Save to List
    Saved in:
  4. 984
    Genes with decreased expression in TGFβ-induced EMT.

    Genes with decreased expression in TGFβ-induced EMT. by Kevin A. Maupin (190060)

    Published 2010
    Save to List
    Saved in:
  5. 985
    Substance P decreases PRL immunoreactivity in human epidermis.

    Substance P decreases PRL immunoreactivity in human epidermis. by Ewan A. Langan (405804)

    Published 2013
    “…<p>Epidermal PRL IR (black arrows) was examined in full-thickness human skin organ culture. (A) PRL IR in the control group was significantly greater than that in (B) Substance P treated skin. …”
    Save to List
    Saved in:
  6. 986
    Adverse events in low-dose naltrexone arm.

    Adverse events in low-dose naltrexone arm. by Judith I. Tsui (5983160)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  7. 987
    CONSORT flow diagram.

    CONSORT flow diagram. by Judith I. Tsui (5983160)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  8. 988
    Adverse events in placebo arm.

    Adverse events in placebo arm. by Judith I. Tsui (5983160)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  9. 989
    Mean pain interference overtime (baseline to 12 weeks).

    Mean pain interference overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  10. 990
    Medication tolerability, discontinuations, adherence over the 8-week study period.

    Medication tolerability, discontinuations, adherence over the 8-week study period. by Judith I. Tsui (5983160)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  11. 991
    Mean cold pressor threshold overtime (baseline to 12 weeks).

    Mean cold pressor threshold overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 992
    Adverse events in gabapentin arm.

    Adverse events in gabapentin arm. by Judith I. Tsui (5983160)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  13. 993
    Medication satisfaction over 8-week study medication period.

    Medication satisfaction over 8-week study medication period. by Judith I. Tsui (5983160)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  14. 994
    Mean in cold pressor tolerance overtime (baseline to 12 weeks).

    Mean in cold pressor tolerance overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 995
    Mean change in pain severity and interference from baseline to 8 weeks.

    Mean change in pain severity and interference from baseline to 8 weeks. by Judith I. Tsui (5983160)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 996
    Main results: Changes in primary and secondary outcomes from baseline to 8 weeks in the PETER PAIN trial.

    Main results: Changes in primary and secondary outcomes from baseline to 8 weeks in the PETER PAIN trial. by Judith I. Tsui (5983160)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 997
    Baseline characteristics of PETER PAIN study participants: People with HIV, chronic pain, and heavy alcohol use (n = 45).

    Baseline characteristics of PETER PAIN study participants: People with HIV, chronic pain, and heavy alcohol use (n = 45). by Judith I. Tsui (5983160)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 998
    Mean pain severity overtime (baseline to 12 weeks).

    Mean pain severity overtime (baseline to 12 weeks). by Judith I. Tsui (5983160)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 999
    Cells with higher expression of a housekeeping gene have a decreased expression of viral genes.

    Cells with higher expression of a housekeeping gene have a decreased expression of viral genes. by Efrat M. Cohen (3384470)

    Published 2016
    Save to List
    Saved in:
  20. 1000
    A low dose of BCNU decreases division and promotes differentiation of O-2A/OPCs

    A low dose of BCNU decreases division and promotes differentiation of O-2A/OPCs by Joerg Dietrich (35101)

    Published 2011
    Save to List
    Saved in:

Search Tools: